Cleared Traditional

K944606 - CX OPIATE REAGENT FOR SYNCHRON CX SYSTEMS

K944606 is an FDA 510(k) clearance for CX OPIATE REAGENT FOR SYNCHRON CX SYSTEMS, manufactured by Beckman-Diagnostic Systems Group. The device is a Class 2 Toxicology device with product code DJG cleared through the Traditional 510(k) pathway after a 72-day FDA review.

K944606 · Beckman-Diagnostic Systems Group · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1994
Decision
72d
Days
Class 2
Risk

K944606 is an FDA 510(k) clearance for the CX OPIATE REAGENT FOR SYNCHRON CX SYSTEMS. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Beckman-Diagnostic Systems Group (Brea, US). The FDA issued a Cleared decision on November 30, 1994 after a review of 72 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Beckman-Diagnostic Systems Group devices

FDA 510(k) Submission Details - K944606

510(k) Number K944606 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 19, 1994
Decision Date November 30, 1994
Days to Decision 72 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
15d faster than avg
Panel avg: 87d · This submission: 72d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DJG Device Classification - Class 2, Special Controls

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 194
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K944606.
ABUSIGN(TM) OPI, DOA-OPI, ACCUSIGN(TM) OPI, DOA-OPI, BIOSIGN(TM) OPI, DOA-OPI
K945608 · Princeton BioMeditech Corp. · Feb 1995
VISUALINE II MORPHINE/OPIATES/HEROIN
K943248 · Sun Biomedical Laboratories, Inc. · Jan 1995
CEDIA DAU OPIATE ASSAY
K945343 · Microgenics Corp. · Jan 1995
CEDIA DAU OPIATE ASSAY
K941195 · Microgenics Corp. · Sep 1994
CEDIA(R) DAU OPIATE ASSAY
K935346 · Microgenics Corp. · Jan 1994
EMIT(R) IIC OPIATE ASSAY
K935117 · Syva Co. · Jan 1994